Bebtelovimab fights COVID subvariant now dominant in Massachusetts
April 18, 2022
This article is for all providers caring for our members
According to the latest Commonwealth of Massachusetts Department of Public Health guidance, for patients for whom current preferred antiviral treatments (nirmatrevlivr/ritonavir or remdesevir) aren’t appropriate or available, the preferred monoclonal antibody treatment is Bebtelovimab.
Laboratory data has shown Bebtelovimab retains efficacy with a broad range of COVID variants, including Omicron BA.2, which is now dominant in Massachusetts. Bebtelovimab is a newer antibody treatment with emergency use authorization to be given by IV within 7 days of a patient’s first COVID symptoms.
More information
- MA Department of Public Health: Clinical Guidance on Therapeutics for COVID-19 Issued March 25, 2022
- Provider Central: COVID-19 treatments available across Massachusetts
- Coverage health news site: What you should know about COVID treatments
MPC_030620-1N-230